Vistin Pharma ASA (DE:VP4) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vistin Pharma ASA reported a decline in revenue for Q3 2024 to MNOK 106, down from MNOK 120 in the same quarter last year, due to lower sales volume and global Metformin prices. Despite this, the company achieved a record high EBITDA of MNOK 29, attributed to a favorable product mix and cost control, and announced an additional dividend of NOK 0.50 per share for Q4. The company’s operational efficiency was highlighted by an all-time high production volume of 1500MT.
For further insights into DE:VP4 stock, check out TipRanks’ Stock Analysis page.